«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

1994年第1期

页码:

37-41

栏目:

综述

出版日期:

1994-01-01

文章信息/Info

Title:

-

作者:

吉文庆¹ 综述 黄定九² 审校

1南京大学医学院鼓楼医院心脏科 南京 210008 2上海第二医科大学仁济医院心内科

Author(s):

-

关键词:

-

Keywords:

-

分类号:

-

DOI:

-

文献标识码:

-

摘要:

-

Abstract:

-

参考文献/References

［1］Baim DS et al.Evaluatien of a new bipyridine inotropic agent：milrinonein patients with severe congestive heart faiture.N Engl J Med 1983;3O9:748.

［2］Braunweld E．Newer Positive inotrepic agent：introduction．Circulation 1986;73(suppl Ⅲ):l.

［3］Farah Alousi AA．et a1．New cardiotolic agent：a resorach for digital is substitute．Life sci 1978;22：1139.

［4］Jaski BE。et a1．Positive inotropic and vasodilator agents of milrinone in patients with severe congestive heart failure.J Clinn Invest 1985：75：643.

［5］Timmis AD,et al．Milrinone in heart failure:Acute effects on left ventricular systolic functien and myocardial metabolism.Br Heart J l985：54：36.

［6］Cody BJ，et al．Identification of the dlrect vasodlIator effect ot milrinone with an isolated limb Preparatien in patients with chronic congestive heart failure. Ann Intern Med 1984：10l:370.

［7］Celuoci WS.et a1.Milrinone and dobutamine in severe heart failure:Differing hemodynamic effects and individual patient responsiveness.Circulation 1986；73(suppl Ⅲ)：175.

[8]Longhurst JC,Cardiac respectors:their function in heart and disease.Prog Cardiovasc Dis 1984：27：201.

[9]Lejemtel TH，et a1.Systemic and regional hemodynamic effect of captoprll and milrinone administed alone and concomitantly in patients with heart failure.Circulation 1985：72：364.

[10]Ludmer PL．et al．Separation of the dlrect myocardial and vasodilation actions of milrinone administed by an intracoronary infusion technique.Circulation 1986;73:130.

[11]Monnad ES．et al.Improvement in indexes of diasto1ic Performance in patients with congestive heart failure．Circulation 1984：70:1030.

[12]Piscione F，et a1．Effect of a single oral dose of milrinone on left ventricular diastolic performance in the failure human heart．JACC 1987;10:1294.

[13]Monrad ES，et a1．Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure.Circulation 1985：71:972.

[14]Baim DS．Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow．Am J Cardiol 1989：63：23A.

[15] Bcave JA，et a1．Primary sequenco of cyclic nucleotide phosphodiesterase isoenzymes and the design of solective inhibitors．Trends Pharmacol Sci 1990；11：150.

[16] Erhardt PW，et a1．Cardiotonic agents：A topographical model of the cardiac cAMP phosphodiesterase receptor.Medt Pharmacol 1988：33：1.

[17]Honerjager P．Pharmacology of positive inotropic phosphodiesterase inhibitors,Eur Heart J 1989：10：25.

[18] Harris AL etal．The vasorelaxant effects of milrinone and other vasodilatore are attenuated by ouabain.Eur J Pharmacol 1988：145：133.

[19]Kauffman RF。et al．In vitro vascular relaxation by new inotropic agents：relationship to phosphodiesterase inhibiton and eyclic nucleotides.J Pharmacol Exp Ther 1987;242:864.

[20]Lejemtel TH，et al.Effects of phosphodiesterase inhibitor on skeletal muscle vasculation．Am J Cardiol 1989：63：27A.

[21]Gwathiney JK，et a1．Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure.Circ Res 1987;61:70.

[22]Benotti JB．et a1．Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure．Am J Cardiol 1985：56：685.

[23]Shotz H．et a1.Phosphodiesteraseinhibiting properties of newer inotropic agents．circulation 1986;73(suppl Ⅲ：99.

[24]Davidenko JM．et al．The effects of milrinone on conduction，reflection and automaticity in canine Purkinje-fiber.Circulation 1984：69：1026.

[25]Goldstein RA，et a1．Electrophysiologic efects of milrinone in patients with congestive heart failure．Am J Cardiol 1986：57：624.

[26]Slroshame RM,et a1.Oral and intravenous pharmacokinetics of milrinone in human volunteers．J Pharm Sci 1984；73：1438.

[27]Edelson J,et a1．Pharmacokinetics of the bipyridines amrinone and milrinone.Circulation 1986：73(suppl Ⅲ)：145.

[28]White HD．et a1．Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure.Am J Cardiol 1985：56：93.

[29]Jewitt．DE，et al.Therapeutic achievement of phosphodiesterase，Phosphodiesterase inhibitors and the future．Eur Heart J 1989：10(suppl c)：53.

［30］Dibianco R,Clinical results with oral milrinono in heart failure.Eur Heart J 1989：10(suppl c)：44.

备注/Memo

备注/Memo:

收稿 1993-08-16

常用功能

更新日期/Last Update: 1994-01-01